key: cord-0915382-w1fzp66t authors: Sheikh, Daniya; Tripathi, Nishita; Chandler, Thomas R.; Furmanek, Stephen; Bordon, Jose; Ramirez, Julio A.; Cavallazzi, Rodrigo title: Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia date: 2021-12-09 journal: Respir Med DOI: 10.1016/j.rmed.2021.106714 sha: 2c8c91a8368d9e82cee29e3b5047f928f51d0ad5 doc_id: 915382 cord_uid: w1fzp66t BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have poor outcomes in the setting of community-acquired pneumonia (CAP) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary objective is to compare outcomes of SARS-CoV-2 CAP and non-SARS-CoV-2 CAP in patients with COPD. The secondary objective is to compare outcomes of SARS-CoV-2 CAP with and without COPD. METHODS: In this analysis of two observational studies, three cohorts were analyzed: (1) patients with COPD and SARS-CoV-2 CAP; (2) patients with COPD and non-SARS-CoV-2 CAP; and (3) patients with SARS-CoV-2 CAP without COPD. Outcomes included length of stay, ICU admission, cardiac events, and in-hospital mortality. RESULTS: Ninety-six patients with COPD and SARS-CoV-2 CAP were compared to 1129 patients with COPD and non-SARS-CoV-2 CAP. 536 patients without COPD and SARS-CoV-2 CAP were analyzed for the secondary objective. Patients with COPD and SARS-CoV-2 CAP had longer hospital stay (15 vs 5 days, p < 0.001), 4.98 higher odds of cardiac events (95% CI: 3.74–6.69), and 7.31 higher odds of death (95% CI: 5.36–10.12) in comparison to patients with COPD and non-SARS-CoV-2 CAP. In patients with SARS-CoV-2 CAP, presence of COPD was associated with 1.74 (95% CI: 1.39–2.19) higher odds of ICU admission and 1.47 (95% CI: 1.05–2.05) higher odds of death. CONCLUSION: In patients with COPD and CAP, presence of SARS-CoV-2 as an etiologic agent is associated with more cardiovascular events, longer hospital stay, and seven-fold increase in mortality. In patients with SARS-CoV-2 CAP, presence of COPD is associated with 1.5-fold increase in mortality. Chronic obstructive pulmonary disease (COPD) is a common disease with a global prevalence of 2% in women and 3.2% in men [1, 2] . In the United States, the prevalence of COPD varies largely among states, some of which have figures higher than 9% [3] . Patients with COPD have an 18 times higher risk of developing Community-acquired Pneumonia (CAP) requiring hospitalization as compared with patients without COPD [4] . In fact, COPD is the strongest risk factor for development of CAP requiring hospitalization [1, 4, 5] . Overall, a third of patients with CAP requiring hospitalization die within a year, and the mortality is 25% greater among patients with COPD [4, 5] . The year of 2020 was distinguished by the emergence of the Coronavirus Disease 2019 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [6] . As of February 2021, this unprecedented pandemic has caused over 500,000 deaths only in the United States [7] . The predominant clinical manifestation of COVID-19 is respiratory tract infection. In the severe form, patients develop CAP with consequent respiratory failure [8] . Most reports so far indicate COPD is associated with higher mortality in the setting of SARS-CoV-2 infection. But it is not clear how the outcomes of SARS-CoV-2 CAP compare with those of non-SARS-CoV-2 CAP in patients with COPD. Such a comparison will enable a more complete understanding of the interaction between COPD and SARS-CoV-2 in the setting of CAP. The primary objective of our study is to compare the clinical outcomes of SARS-CoV-2 CAP and non-SARS-CoV-2 CAP in patients with COPD. The secondary objective is to compare the outcomes of SARS-CoV-2 CAP in patients with and without COPD. This comparative analysis involved a combination of two large observational studies: the Burden of COVID-19 study [9] and the University of Louisville Pneumonia Study. [ We selected patients who were hospitalized with CAP. Patients with COPD were selected based on the diagnosis from the electronic medical record. The diagnosis of CAP required the presence of a new pulmonary infiltrate on imaging (computed tomography scan or chest X-ray) at the time of admission to the hospital with at least one of the following signs or symptoms: new or increased cough (per history), a temperature of >37.8 C or <35.6 C, or abnormality in leukocyte count (>11,000 or <4000 cells/mL, or left shift with >10% band forms/mL). For our analysis, patients with CAP who were admitted prior to the COVID-19 pandemic onset were considered as non-SARS-CoV-2 CAP. A patient was defined as having COVID-19 when the virus SARS-CoV-2 was identified in a clinical specimen using polymerase chain reaction. Additionally, to match the time frame for the Burden of COVID-19 study, only patients from the The patients in our study were divided into 3 groups. The first group consisted of patients who had SARS-CoV-2 CAP and COPD and was derived from the Burden of COVID-19 study. The second group consisted of patients who had COPD and non-SARS-CoV-2 CAP, who were taken from the University of Louisville Pneumonia Study database. The third group consisted of patients with SARS-CoV-2 CAP without COPD and was obtained from the Burden of COVID-19 study. Study variables collected from the medical records included demographics, comorbidities, medications, vital signs, laboratory values and the following severity of disease indicators: invasive or non-invasive ventilator support on the first day of admission, vasopressors (e.g. epinephrine, norepinephrine, and phenylephrine) on the first day of admission, and pneumonia severity index (PSI) risk class [10] . Study outcomes included intensive care unit (ICU) admission, need for invasive mechanical ventilation, hospital length of stay (LOS), cardiovascular events and all-cause inhospital mortality. Cardiovascular events were defined as any in-hospital events occurring from J o u r n a l P r e -p r o o f the onset of symptoms until discharge. The cardiovascular events considered for the analysis included acute myocardial infarction, pulmonary edema due to congestive heart failure, occurrence of a new serious arrhythmia, acute worsening of long-term arrhythmia, cerebrovascular accidents (e.g. ischemic/hemorrhagic stroke) and pulmonary emboli. LOS was defined in days and was calculated for each patient as the day of discharge minus the day of admission. LOS was treated as a time-dependent outcome and right truncated at 30 days. A patient who died in hospital was given a censored 30-day LOS as a worst outcome. For the SARS-CoV-2 CAP groups, patients who were discharged to hospice were also censored at 30 days. In-hospital mortality was defined as all-cause mortality occurring during the hospitalization. Continuous patient characteristics were summarized as median and interquartile range. Categorical patient characteristics were summarized as frequencies and percentages. Baseline patient characteristics were compared using Chi-Squared tests of independence, or Fisher's exact test when expected cell counts were insufficient. Adjusted analysis included inverse-propensityweighted (IPW) logistic regressions for categorical outcomes adjusted for pneumonia severity index and reported as an IPW odds ratio (IPW-OR). Length of stay was analyzed using IPW survival estimation and an IPW log-rank test from the RISCA package in R. [11] Full details for inverse propensity score weighting are provided in the supplemental material. Analysis was performed with R version 3.4.0. [12] P-values were 2-sided, with statistical significance set at P < 0.05. Patient characteristics are shown in Table 1 . Higher proportions of black race (32%, n = 31), nursing home residents (30%, n = 29), and a history of obesity (48%, n = 46), diabetes mellitus (51%, n = 49), renal disease (41%, n = 39), essential arterial hypertension (80%, n = 77), and substance abuse (14%, n = 13) were present in patients with COPD and SARS-CoV-2 CAP as compared with patients with COPD and non-SARS-CoV-2 CAP. Patients with COPD and SARS-CoV-2 CAP presented with higher PSI scores (median = 118, IQR = 86 -137) and lower serum glucose (median = 120 mg/dL, IQR = 102 -171) as compared with patients with COPD and non-SARS-CoV-2 CAP. The latter were more likely to be current smokers (40%, n= 451) and have coronary artery disease (34%, n=389) than patients with COPD and SARS-CoV-2 CAP. Patients with COPD and non-SARS-CoV-2 CAP patients also had increased white blood cell counts (median = 12.4 x 1000/uL, IQR = 8.8 -16.7). Patient characteristics are shown in Table E3 Cardiovascular events were also more numerous in the SARS-CoV-2 CAP patient group. A total of 28 (29%) of patients in that group experienced cardiovascular events, compared to 81 (7%) patients in the non-SARS-CoV-2 CAP group. After IPW and PSI adjustment, there were no significant differences in cardiovascular events and need for invasive mechanical ventilation between the two groups (see Figure 2 ). Figure E3 in supplemental material displays the IPW Kaplan-Meier curves for length of stay. After IPW adjustment, this difference in length of stay was not statistically significant (p = 0.200, see Figure E3 ). Our analysis showed that patients with COPD and SARS-CoV-2 CAP had seven times higher risk of in-hospital mortality compared to patients with COPD and non-SARS-CoV-2 CAP in previous years. We found that patients with COPD and SARS-CoV-2 CAP had nearly twice the risk of requiring invasive mechanical ventilation, 2.5 times the risk of admission to the ICU, 5 times the risk of experiencing cardiovascular events and three times the median length of stay J o u r n a l P r e -p r o o f compared to patients with COPD and non-SARS-CoV-2 CAP. Additionally, we demonstrated that in patients with SARS-CoV-2 CAP, the presence of COPD is associated with a 74% increase in need for ICU admission and a 47% increase in in-hospital mortality. The increase in mortality in patients with COPD and SARS-CoV-2 CAP in our study may be explained by several biological mechanisms. The use of receptor angiotensin-converting enzyme-2 for SARS-CoV-2 cell entry [13] and the upregulated ACE-2 expression in patients with COPD may be factors predisposing these patients to poor outcomes. The ACE-2 expression in patients with COPD can be upregulated by two mechanisms. First, chronic exposure to smoke causes expansion of ACE-2 secretory cells [14] . Second, cigarette smoke, by virtue of its pro-inflammatory nature, promotes the production of inflammatory mediators, which trigger an upregulation of ACE-2 receptors [15] . Additionally, patients with COPD have low basal lung function, damaged airways and dysfunctional immunity caused by smoking, [16] all of which are conducive to SARS-CoV-2 infection and poor outcomes from it [17, 18] . Other studies have assessed the impact of COPD on mortality in hospitalized patients with SARS-CoV-2 infection. Taken together, these studies, like ours, indicate that the presence of COPD is associated with a 1.3 to 2.7 fold increased risk of in-hospital mortality [17] [18] [19] [20] [21] [22] [23] . But our own data shows that COPD is not associated with increased mortality in non-SARS-CoV-2 CAP in the short-term [4] . These findings suggest that SARS-CoV-2 modifies the short-term deleterious effects of COPD in patients with CAP. It is important to note that during pandemic surges, resource limitations likely had an impact on the outcomes of patients with COVID-19 in some areas of the country. However, the healthcare system in the city Louisville remained in good shape during that time. The high frequency of cardiovascular events in patients with COPD and SARS-CoV-2 CAP found in our study could be attributed to a variety of mechanisms. Earlier in the pandemic, increased cytokine levels described in patients with COVID-19 were proposed as a mechanism of COVID-19 induced organ dysfunction. However, it was more recently demonstrated that even though cytokine levels are increased in patients with COVID-19, they are not necessarily higher than those of other critically ill patients with acute respiratory failure [24] . Thrombotic microangiopathy seems to play a more important role. As an example, a post-mortem study showed a distinctive feature of lung injury caused by SARS-CoV-2 is the presence of disseminated thrombosis with microangiopathy in the pulmonary vessels, and angiogenesis [25] . Clinically, patients with COVID-19 often have elevated levels of D-dimer, and their levels are on aggregate higher than those of patients with sepsis from other etiologies [24] . Chronic hypoxia, augmented inflammation, and right ventricular dysfunction [26] are commonly present features in patients with COPD and can compound the increased predisposition to cardiovascular events imparted by SARS-CoV-2 infection. One of the most contrasting results between SARS-CoV-2 CAP and non-SARS-CoV-2 CAP in patients with COPD in our study was length of stay. The prolonged length of stay in patients with SARS-CoV-2 infection is driven by respiratory failure, which in the early phase is characterized by perfusion impairment causing ventilation-perfusion mismatch and increased dead space. Other features in the early phase include high minute-ventilation and relative high lung compliance. Later in the course of the disease, the acute respiratory failure may evolve into a pattern that resembles traditional acute respiratory distress syndrome with low lung compliance and positive end-expiratory pressure (PEEP) responsiveness [27] . The prolonged hospital stay in patients with SARS-CoV-2 infection is not unique to patients with COPD. For instance, in a J o u r n a l P r e -p r o o f clinical trial that included hospitalized patients with SARS-CoV-2 infection, the experimental arm had a median length of hospital stay of 12 days. In those requiring mechanical ventilation or extracorporeal membrane oxygenation, the median length of hospital stay was 17 days [28] . The impact that the COVID-19 pandemic has had in residents of assisted living facilities cannot be overstated. In our study, approximately one third of the patients with COPD and SARS-CoV-2 infection came from nursing homes. According to a report from Centers for Disease Control and Prevention (CDC), 1 out of 5 assisted living facility residents with COVID-19 have died whereas there has been 1 death out of 40 in persons with COVID-19 in the general population [29] . Another important epidemiological feature from our study is that there was a substantially higher proportion of blacks in the group of patients with COPD and SARS-CoV-2 CAP as compared to the group of COPD and non-SARS-CoV-2. This in line with populationbased data from the CDC. Compared with white, non-Hispanic persons, the rate of hospitalization by COVID-19 was 3.2 times higher in Hispanic persons, 2.9 times higher in black persons, and 3.7 times higher in American Indian or Alaska Native persons [30] .These numbers lay bare the health disparities experienced by these groups, which largely reflect their lower social economic status, higher proportions in service occupations [31], lower access to health care [32] , and residential segregation [33] . The latter is particularly pervasive in Louisville where there are minority populated neighborhoods without access to healthy food [34] . Our study has limitations. The main limitation of our study is the lack of data regarding COPD severity from our study cohorts. While we were able to capture chronic steroid use and need for home oxygen therapy prior to hospitalization, we were unable to collect data on FEV1, FVC, and other common markers of severity among patients with COPD. The diagnosis of J o u r n a l P r e -p r o o f COPD was not confirmed by spirometry, which could lead to misclassification bias. The latter would be non-differential as both groups were susceptible to it. However, it has been previously shown that a self-reported history of COPD highly increases the likelihood that COPD will be confirmed if a spirometry is performed [35] . There was an approximate 4 years difference between the two studies that provided the cohorts for the current analysis, a time frame in which treatment and outcomes could have evolved. Additionally, our study highlights the initial management of COVID-19 in hospitalized patients, which is constantly evolving. Strengths of the study include its comprehensive datasets with a wealth of clinical data not generally found in studies relying on administrative datasets. The study was multicenter and encompassed all adult hospitals in the city. Furthermore, the epidemiology of the city of Louisville resembles that of the United States [36] . In summary, our analysis showed that inpatients with COPD and CAP, the presence of SARS-CoV-2 infection is associated with more cardiovascular events, higher ICU admission rates, higher need for mechanical ventilation, longer hospital length of stay, and a staggering 7fold increase in hospital mortality. Furthermore, in patients with SARS-CoV-2 CAP, the presence of COPD is associated with a 1.5-fold increase in hospital mortality. Our data clarifies the interaction between SARS-CoV-2 and COPD in the setting of CAP and highlights the need for vaccination and other prevention efforts to avoid CAP in patients with COPD. [20, 28] 23 [20, 28] 0.321 ( COPD: Chronic obstructive pulmonary disease; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2. The black line depicts time to discharge for patients with SARS-CoV-2 CAP. The dashed gray line depicts time to discharge for patients with non-SARS-CoV-2 CAP. The horizontal dotted line represents the time at which 50% of the patients have been discharged from the hospital per group. The test statistic comes from inverse-propensity score weighted logrank tests comparing the two curves. Community-acquired pneumonia in chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study Chronic Obstructive Pulmonary Disease (COPD) Data and Statistics Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality SARS-CoV-2 is an appropriate name for the new coronavirus Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Characteristics and Outcomes of Adults Hospitalized with SARS-CoV-2 Community-Acquired Pneumonia in A prediction rule to identify low-risk patients with community-acquired pneumonia RISCA: Causal Inference and Prediction in Cohort-Based Analyses R: A language and environment for statistical computing SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction Clinical Characteristics and Outcomes of Patients with Severe COVID-19 and Chronic Obstructive Pulmonary Disease (COPD) Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study Impact of COPD on COVID-19 prognosis: A nationwide populationbased study in South Korea Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2 Prognostic Factors at Admission for In-Hospital Mortality from COVID-19 Infection in an Older Rural Population in Central Spain Higher comorbidities and early death in hospitalized African-American patients with Covid-19 Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease Management of COVID-19 Respiratory Distress Remdesivir for the Treatment of Covid-19 -Final Report Characterization of COVID-19 in Assisted Living Facilities -39 States COVID-19 hospitalization and death by race/ethnicity. 2021 Changes in health coverage by race and ethnicity since the ACA Racial residential segregation: a fundamental cause of racial disparities in health Why it's Easier to Get a Burger than Broccoli on West Broadway: The geography of food insecurity in Louisville The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease The City of Louisville Encapsulates the United States Demographics. The University of Louisville Journal of Respiratory Infections Systolic Blood Pressure (mmHg) * 119 Diastolic Blood Pressure (mmHg) * 63 Glucose (mg/dL) * 120 Blood urea nitrogen (mg/dL) * 25 CAP: community-acquired pneumonia; COPD: chronic obstructive pulmonary disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ACE inhibitors: angiotensinconverting enzyme inhibitors; WBC: white blood cells PaO2/FiO2: pressure of arterial oxygen to fractional inspired oxygen concentration Systolic Blood Pressure (mmHg) * 119 Diastolic Blood Pressure (mmHg) * 63 Glucose (mg/dL) * 120 Blood urea nitrogen (mg/dL) * 25 CAP: community-acquired pneumonia; COPD: chronic obstructive pulmonary disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ACE inhibitors: angiotensinconverting enzyme inhibitors; WBC: white blood cells We would like to thank the research associates working at the Center of Excellence for Research in Infectious Diseases (CERID) for data collection and quality control. We also thank the support of the Infectious Diseases division at the University of Louisville.J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f